Molecular Therapy of Breast Cancer: Classicism Meets Modernity (newbook)
NEW BOOK ! (September 2009)
Molecular Therapy of Breast Cancer: Classicism Meets Modernity
(by Marc Lacroix)
Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0
(hardcover): [Only registered users see links. ]
(online book): [Only registered users see links. ]
Breast cancer is the most frequently diagnosed type of cancer and a
second leading cause of cancer death in women after lung cancer.
Despite their proven efficacy, classical therapies are, however,
unable to cure metastatic breast cancer and are often associated with
significant toxicity and side-effects, due to a wide spectrum of
action. During the last years, our increasing knowledge of the
molecular pathways underlying cancer development has led to the
introduction of new drugs, of which most are directed towards very
specific targets. Rather than to be used as single agents, these
“modern” compounds could ultimately be combined with “classical”
Here are described nearly 150 drugs that are currently (2009) used in
routine therapy or are in clinical trials in breast cancer patients.
From the classical tamoxifen, fluorouracil, cyclophosphamide,
doxorubicin, epirubin, docetaxel, paclitaxel…, to the more recently
introduced ixabepilone, lapatinib, vorinostat, everolimus,
bevacizumab…, they also include capecitabine, gemcitabine,
trastuzumab, fulvestrant, aromatase inhibitors, cancer vaccines,
inhibitors of tumor-induced osteolysis, insulin-like growth factor-I
receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors,
and many others.
This book offers an insight into current developments of breast cancer
therapy, when classicism meets modernity.